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ABSTRACT
Objective: To translate and to perform the cross-cultural adaptation of the “Questionnaire of Life Quality Specific for Myasthenia Gravis - 15 
items” (MG-QOL15). Method: The original English version of the questionnaire was translated into Portuguese. This version was revised and 
translated back into English. Later, both English versions were compared and the divergences were corrected in the Portuguese text. At a 
second stage, ten patients with MG followed at the Neuromuscular Diseases Clinic from the University Hospital, Universidade Federal de 
Minas Gerais answered the questionnaire. The authors analyzed the difficulties and misunderstandings in the application of the question-
naire. Results: The questions 8, 13 and 15 were considered difficult to understand and were modified in the final Portuguese version. Most 
patients (70%) had a total score above 25, and the statements 3, 8 and 9 showed the highest scores. Conclusion: The Brazilian version of the 
questionnaire MG-QOL15 seems to be a promising tool for the assessment of Brazilian patients with MG. 
Keywords: myasthenia gravis, quality of life, questionnaire.
RESuMo
Objetivo: Realizar a tradução e a adaptação transcultural do “Questionário de Qualidade de Vida Específico para Miastenia Gravis – 15 itens” 
(MG-QOL15). Método: Inicialmente, foi realizada a tradução do instrumento original em inglês para o português. Esta versão foi revisada e 
retrotraduzida para o inglês. A versão retrotraduzida foi comparada à versão original em inglês, sendo corrigidas as divergências no texto em 
português. Em um segundo momento, dez pacientes com MG acompanhados na Clínica de Doenças Neuromusculares do Hospital das Clíni-
cas da Universidade Federal de Minas Gerais responderam ao questionário. Na aplicação do questionário, os itens mal compreendidos foram 
analisados pelos autores. Resultados: Os itens 8, 13 e 15 foram considerados de difícil compreensão e modificados na versão final em por-
tuguês. A maioria dos pacientes (70%) apresentou uma pontuação total superior a 25, sendo que os itens 3, 8 e 9 apresentaram os escores 
mais elevados. Conclusão: A versão brasileira do MG-QOL15 é um instrumento promissor para a avaliação de pacientes brasileiros com MG. 
Palavras-chave: miastenia gravis, qualidade de vida, questionário. 
Myasthenia Gravis (MG) is an autoimmune neuromus-
cular junction disorder that results in fatigue and fluctuating 
weakness. The incidence of MG varies according to sex, age, 
and ethnic group1-6, with an annual incidence ranging from 
1 to 15 cases per million7,8. The disease is more prevalent in 
young women when compared to men, with a gender ratio of 
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approximately 2:19. It is also reported to be common in elder-
ly men1,2,5. Over the past decades, advances in treatment have 
changed the prognosis of MG, but spontaneous remission is 
not frequent and the impact on the quality of life of patients 
still significant10.
The report of the quality of life by the patient may in­
fluence therapeutic decisions and enable a better understan­
ding of his/her demands, paving the way for an optimal clini-
cal support11,12. The more specific the questionnaire, the more 
likely it includes only items relevant to the disease, avoiding 
unnecessary statements13.
The aim of the current study is to perform the transla­
tion and cross-cultural adaptation of an instrument desig-
ned to specifically assess the quality of life of MG patients 
named “Questionnaire of Life Quality Specific for Myas­
thenia Gravis - 15 items” (MG-QOL15)12. We expect this 
instrument may contribute to the evaluation of patients 
in both clinical and research settings, providing a reliable 
view on the physical, psychological and social well­being of 
Brazilian patients with MG.
METhod
Instrument
The MG­QOL1512 originated from a list of 60 items co ve-
ring specific features of health related­quality of life in MG. The 
main objective of MG­QOL15 is to provide an effec tive, fast 
and easy way to evaluate, and to interpret the quality of life 
of MG patients. Each item is scored from zero to four accor-
ding to its frequency, scoring a maximum of 60. The higher the 
score, the worse it is perceived the quality of life by the patient.
Translation, reverse translation and final version
To translate the MG­QOL15 into Portuguese, two authors 
performed independently the initial translation of the instru-
ment. Both versions were then reviewed by a third author to 
build a single revised version in Portuguese. This revised ver-
sion was back­translated into English by a fourth author. The re-
verse-translated version was compared to the original English 
version, and any discrepancy was corrected in the Portuguese 
text to keep the original meaning. This final Portuguese ver-
sion was used in the testing phase described bellow.
Testing phase
We randomly recruited ten patients over 18 years­old 
who are followed at the Neuromuscular Diseases Clinic of the 
University Hospital, Universidade Federal de Minas Gerais, 
Belo Horizonte, Brazil.
The following demographic and clinical data were col-
lected: age, gender, marital status, educational level, early 
and current symptoms of MG, and therapeutic strategies. 
MG was categorized according to the Myasthenia Gravis 
Foundation of America Clinical Classification (MGFA)1. The 
MG Composite13 was used to assess the current severity of 
MG clinical signs and symptoms. In addition, the Medical 
Outcomes Study 36­Item Short­Form Health Survey (SF­36)14 
and the Hospital Anxiety and Depression Scale (HADS)15 
were applied. SF­36 is one of the most widely used instru-
ments to assess quality of life in clinical and research settings, 
being composed of eight health related domains (physical 
functioning, role­physical, bodily pain, general health, vitali-
ty, social functioning, role­emotional and mental health). The 
HADS comprises 14 items, seven to assess anxiety (HAD­A) 
and seven depression (HAD­D).
MG-QOL15 was applied to 10 patients with MG. Patients 
commented on their difficulties in understanding each state-
ment and the misunderstood items were pointed out and 
subsequently revised by the authors. The objective of this 
step was to verify whether each item was clearly understood 
and consistent with its original meaning.
The study was approved by the Research Ethics Com­
mittee of the Universidade Federal de Minas Gerais (ETIC no. 
0476.0.203.000­11). All subjects gave their written informed 
consent to participate in the study.
RESuLTS
The clinical and socio­demographic features of the pa-
tients are depicted in Table 1. Nine patients (90%) were fe-
male, aged 25 to 57 years­old, and 80% attended at least 8 
Table 1. Clinical and demographic features of the patients with 
myasthenia gravis (n=10) participating in the current study.




Age 18 – 50 6 60
Age > 50 4 40








Mean MG composite 13




Azathioprine + Prednisone 6 60
Prednisone 4 40
MG: myasthenia gravis; MGFA: Myasthenia Gravis Foundation of America 
Clinical Classification; HADS: Hospital Anxiety and Depression Scale.
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years of school. Five patients (50%) had ocular symptoms as 
the initial complaint, and seven (70%) reported bulbar mani-
festations as being the main problem.
During testing phase, patients had difficulty in interpre­
ting and understanding the items 8, 13 and 15. As an exam-
ple, regarding the adaptations in statement 8, the expression 
‘professional status’ (original version) was replaced by ‘my 
position at work’ (back­translation version) due to the diffi-
culty of all patients to understand the word ‘status’. To ease 
comprehension, the word “cargo”(meaning job function) was 
introduced in parenthesis after the expression ‘my position 
at work’. After entering the word “cargo”, the comprehension 
became effective. For the analysis and discussion of all state-
ments, meetings were held among the authors, reaching the 
final Portuguese version.
Seven patients had a score above 25 in MG­QOL15, and 
items 3, 5, 7, 8 and 9 showed the highest scores (Table 2). A 
negative correlation was observed between MG-QOL15 and 
total SF­36 score (p<0.05; rho=60) due to a very significant 
correlation between MG-QOL15 and the general health do-
main of SF­36 (p<0.001; rho=91). A significant positive corre-
lation was also observed between MG­QOL15 and the HADS 
(p<0.05; rho=63).
dISCuSSIon 
The MG­QOL15 was originally proposed and published 
in English, being derived from a list of 60 items covering 
features of health related-quality of life in MG16. The ori­
ginal study showed that MG-QOL15 correlated with clini-
cal measures of MG, indicating its construct validity. In the 
current study, we performed the translation and cross­cul-
tural adaptation to Portuguese, and the initial validation 
of the MG-QOL1512.
The Brazilian version of MG­QOL15 was well understood 
and accepted by the patients. To perform a concurrent va-
lidation, MG­QOL15 was correlated with the SF­36. SF­36 
has been already validated in Portuguese and is one of the 
most popular instruments to assess the quality of life rela ted 
to health14. There was a negative correlation between MG­
QOL15 and the general health domain of SF­36. As expected, 
the higher the MG-QOL15 score (i.e. more symptoms and in-
capacity attributed to the disease), the worse the perception 
of the general health status by the patient. This is in line with 
the results of the other two studies with the MG-QOL1512,17. 
Indeed the frequency and severity of MG symptoms are well-
known factors that influence the patient’s perception of 
his/her quality of life1­5,12. Therefore, besides translating and 
adapting MG­QOL15, this study provides preliminary evi-
dence for the validity of the instrument. 
Anxiety disorder and depression are frequent comor-
bid conditions in MG, and they can also influence quality of 
life9,10. The QOLMG­15 correlated positively with the HADS, 
suggesting that the worse the perception of the quality of 
life, the higher the likelihood of being depressed or anxious, 
which is in agreement with the literature9-11. This indicates 
that it is important to look beyond the physical or somatic 
symptoms of the disease in order to provide an optimal clini-
cal assistance to MG patients.
Other disease related­factors may influence quality of 
life in MG such as the type of the predominant symptom, 
the number of myasthenic crisis and drug treatment3­5,12. The 
small number of patients enrolled in this report prevented 
the assessment of these associations, and further investiga-
tion is warranted.
Table 2. Scores of individual items from the “Questionnaire of Life Quality Specific for Myasthenia Gravis - 15 items”. 
Statements (original version) Min-max Mean  (SD)
1. I’m frustrated by my myasthenia gravis. 0-4 1.8 (1.48)
2. I have trouble using my eyes because of my myasthenia gravis. 1-4 2.4 (1.14)
3. I have trouble eating because of my myasthenia gravis. 0-4 2.6 (1.67)
4. I have limited my social activity because of my myasthenia gravis. 0-3 1.0 (1.41)
5. My myasthenia gravis limits my ability to enjoy hobbies and ctivities. 0-4 2.2 (2.04)
6. I have trouble meeting the needs of my family because of my myasthenia gravis. 0-0 1.6 (2.19)
7. I have to make plans around my myasthenia gravis. 0-4 2.4 (2.19)
8. My occupational skills and job status have been negatively affected by my myasthenia gravis. 0-4 3.2 (1.78)
9. I have difficulty speaking due to my myasthenia gravis. 2-4 3.0 (1.0)
10. I have trouble driving due to my myasthenia gravis. 0-0 0.0 (0.0)
11. I am depressed about my myasthenia gravis 0-4 1.4 (1.83)
12. I have trouble walking due to my myasthenia gravis 2-4 2.4 (0.89)
13. I have trouble getting around public places because of my myasthenia gravis. 0-4 1.6 (2.19)
14. I feel overwhelmed by my myasthenia gravis. 0-4 1.4 (1.94)
15. I have trouble performing my personal grooming needs because of myasthenia gravis 0-4 1.2 (1.78)
Total score: 11-46 28.4 (2.53)
SD: standard deviation.
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It is worth mentioning that the authors of the original 
questionnaire did not recommend any cut off value for the 
categorization of the quality of life of patients with MG12. 
They only assumed that the higher the score the worse the 
quality of life, with a maximum score of 60. Despite limited 
sample size, the mean value of MG­QOL15 of our patients 
was similar to the value reported in the original study of 
the instrument12.
In conclusion, this study presents a promising instrument, 
which was easily applied and interpreted by the physician, to 
assess the quality of life in MG. It also indicates that the seve-
rity of motor symptoms and the presence of psychiatric symp-
toms influence the quality of life of Brazilian patients with MG. 
Further studies involving lar ger samples are necessary to vali-
date the MG­QOL15, and to provide more robust data on the 
factors influencing the quality of life in MG.
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